Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Oncology
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective
, 
, , , , , , , & show all
Tassia Cristina Decimonib Health Economics and Outcomes Research, Bristol Myers Squibb, São Paulo, SP, Brazilhttps://orcid.org/0000-0002-0999-9039View further author information
https://orcid.org/0000-0002-0999-9039View further author information, , Jessica R. Mayc WW Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge, UKhttps://orcid.org/0000-0003-0792-7936View further author information
https://orcid.org/0000-0003-0792-7936View further author information, , Svenja Petersohnd Modeling & Meta-Analysis, OPEN Health, Rotterdam, Netherlandshttps://orcid.org/0000-0001-5058-7645View further author information
https://orcid.org/0000-0001-5058-7645View further author information, , , & show all